Aimei Health Technology Co Ltd（AFJK）股票分析

AI 分析 of Aimei Health Technology Co Ltd (AFJK)

持有

Aimei Health Technology Co Ltd (AFJK) is currently not a strong buy. The stock is trading at $12.20, significantly down 83.92% year-to-date, indicating severe volatility and potential instability. The RSI is at 50.187, suggesting it is neither overbought nor oversold, but the forward P/E ratio is 0, indicating a lack of earnings expectations. The company has recently faced negative news, including a failure to file its quarterly report on time and the termination of a merger agreement, which has likely shaken investor confidence. The main risk is the company's recent net income drop to -83,144 USD in Q2 2026, which raises concerns about its financial health. Overall, while there may be potential for recovery, the current situation warrants a cautious approach and a hold position for now.

估值指标

Aimei Health Technology Co Ltd（AFJK）当前预期市盈率为 0.00，5 年平均预期市盈率为 0.00。

预期市盈率

严重低估

5 年均值 P/E

0.00

当前P/E

0.00

高估

0.00

低估

0.00

预期 EV/EBITDA

严重低估

5 年均值 EV/EBITDA

0.00

当前EV/EBITDA

0.00

高估

0.00

低估

0.00

预期市销率

合理

5 年均值 P/S

0.11

当前P/S

0.00

高估

1.24

低估

-1.01

Alphio AI 对 AFJK 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。

乐

乐观

乐观 · 25%AFJK

$14.53

情景价格

基

基准

基准 · 50%AFJK

$12.44

情景价格

悲

悲观

悲观 · 25%AFJK

$10.38

情景价格

持有 AFJK 的大户

W

W. R. Berkley Corporation

+ 持有AFJK

+4.37%

3个月收益率

AFJK 常见问题 —— 由 Alphio AI 解答

Aimei Health Technology Co., Ltd. is a blank check company. The Company is formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. The Company do not have any specific business combination under consideration and has not nor has anyone on behalf, directly or indirectly, contacted any prospective target business. It has not generated any revenues. It operates in the Financials sector.

Aimei Health Technology Co Ltd (AFJK) is currently not a strong buy. The stock is trading at $12.20, significantly down 83.92% year-to-date, indicating severe volatility and potential instability. The RSI is at 50.187, suggesting it is neither overbought nor oversold, but the forward P/E ratio is 0, indicating a lack of earnings expectations. The company has recently faced negative news, including a failure to file its quarterly report on time and the termination of a merger agreement, which has likely shaken investor confidence. The main risk is the company's recent net income drop to -83,144 USD in Q2 2026, which raises concerns about its financial health. Overall, while there may be potential for recovery, the current situation warrants a cautious approach and a hold position for now.